Opendata, web and dolomites

ReHaptix

Easy-to-use and highly accurate medical software for quantitative assessment of impairments in neurologically injured people.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ReHaptix project word cloud

Explore the words cloud of the ReHaptix project. It provides you a very rough idea of what is the project "ReHaptix" about.

mark    plan    aged    lack    functional    healthcare    validity    professionals    validation    perform    hospital       assessments    medical    tablet    injured    supply    device    medication    validated    optimize    solutions    market    clinically    quantitative    progress    strategy    caused    adapt    schedule    worldwide    evidences    grow    monitor    mhealth    remotely    neurologically    drafted    greatest    feasibility    gold    65    obtain    patients    designed    clinic    empowers    standard    parkinson    share    clinical    people    objectively    ms    software    private    treating    recovery    initiated    remote    touchscreen    innovation    accuracy    home    multiple    limited    trials    supervised    hcps    drastically    diseases    app    performing    disorders    expensive    25    rehaptix    appointment    rehabilitation    stroke    sclerosis    disease    neurological    setting    chronic    tests    treatment    ce    chain    impairments    autonomously    either    doctor    30m    percentage    population   

Project "ReHaptix" data sheet

The following table provides information about the project.

Coordinator
REHAPTIX GMBH 

Organization address
address: STAUFFACHERSTRASSE 151
city: ZURICH
postcode: 8004
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Project website http://rehaptix.com/en/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-06-01   to  2019-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    REHAPTIX GMBH CH (ZURICH) coordinator 50˙000.00

Map

Leaflet | Map data © OpenStreetMap contributors, CC-BY-SA, Imagery © Mapbox

 Project objective

Neurological disorders, caused by either stroke, multiple sclerosis (MS) or Parkinson’s diseases affect more than 30M people worldwide. Currently, Europe has the greatest percentage of population aged 65 or over (25%) and these numbers are expected to drastically grow (3% per year) increasing the population affected by these chronic conditions. Neurological rehabilitation is an expensive doctor-supervised program designed for treating these diseases. However, there is currently no effective assessment to objectively measure and monitor the rehabilitation progress. Current solutions for performing assessments do not provide clinical evidences of their validity, show lack of accuracy and are limited to one disease type. ReHaptix has developed a medical software, designed for remote quantitative assessment of impairments in neurologically injured people. ReHaptix has developed 9 tests so far, of which 4 have been clinically validated (the gold standard), and 5 are currently under clinical validation. Healthcare Professionals (HCPs) can use the ReHaptix tests to evaluate their patients in the hospital, rehabilitation clinic or private practice, or patients can perform the tests autonomously at home on a touchscreen tablet, which empowers them about their recovery. Furthermore, patients can remotely share their results with their HCPs, who can adapt the treatment and medication, or schedule medical appointment and home-setting assessments as required. During the feasibility assessment, a go-to-market strategy and a supply chain will be established, as well as further development plan will be drafted. During the second phase of innovation project, ReHaptix will optimize the software increasing the number of tests and developing a functional mHealth app. Clinical trials will then be initiated to obtain the CE mark as a medical device.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "REHAPTIX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "REHAPTIX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

SiC-MOSFET (2019)

Gas Sensors for future Ultra Low NOx Emission Legislation – Euro 7

Read More  

MHS (2019)

Metal Hydrides Hydrogen Storage

Read More  

IMPACT (2019)

Improving DNA Analysis for Correct Healthcare

Read More